NASDAQ:SVRASavara Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.04 +0.01 (+0.49 %) (As of 04/8/2020 01:39 AM ET) Add Compare Share Today's Range$1.94Now: $2.04▼$2.1250-Day Range$1.80MA: $2.32▼$2.7252-Week Range$0.69Now: $2.04▼$11.96Volume340,345 shsAverage Volume523,002 shsMarket Capitalization$103.71 millionP/E RatioN/ADividend YieldN/ABeta0.95 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.60, Savara has a potential upside of 321.6% from its current price of $2.04.Amount of Analyst CoverageSavara has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSavara has received 258 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSavara has received 279 “underperform” votes. (Add your “underperform” vote.)Community SentimentSavara has received 51.96% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote “Outperform” if you believe SVRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Savara is held by insiders.Percentage Held by Institutions40.87% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to decrease by -20.72% in the coming year, from ($1.11) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webhttp://www.savarapharma.com/ Phone512-614-1848Debt Debt-to-Equity Ratio0.23 Current Ratio11.40 Quick Ratio11.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$5.83 per share Price / Cash Flow0.35 Book Value$2.47 per share Price / Book0.83Profitability EPS (Most Recent Fiscal Year)$4.57 Net Income$-78,170,000.00 Net MarginsN/A Return on Equity-48.52% Return on Assets-35.86%Miscellaneous EmployeesN/A Outstanding Shares50,839,000Market Cap$103.71 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive SVRA News and Ratings via Email Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SVRA Rates by TradingView Savara (NASDAQ:SVRA) Frequently Asked Questions How has Savara's stock been impacted by COVID-19 (Coronavirus)? Savara's stock was trading at $2.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SVRA stock has decreased by 13.6% and is now trading at $2.04. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Savara? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Savara. When is Savara's next earnings date? Savara is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Savara. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) announced its quarterly earnings data on Thursday, March, 12th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.31. View Savara's earnings history. What price target have analysts set for SVRA? 6 brokerages have issued 1-year target prices for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they expect Savara's stock price to reach $8.60 in the next twelve months. This suggests a possible upside of 321.6% from the stock's current price. View analysts' price targets for Savara. Has Savara been receiving favorable news coverage? Press coverage about SVRA stock has trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Savara earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSavara. Who are some of Savara's key competitors? Some companies that are related to Savara include Catalyst Pharmaceuticals (CPRX), CytomX Therapeutics (CTMX), Corbus Pharmaceuticals (CRBP), Merus (MRUS), Cue Biopharma (CUE), Avadel Pharmaceuticals (AVDL), Kala Pharmaceuticals (KALA), Beyondspring (BYSI), Viking Therapeutics (VKTX), NewLink Genetics (NLNK), Organogenesis (ORGO), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), Calithera Biosciences (CALA) and Syndax Pharmaceuticals (SNDX). What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), Sorrento Therapeutics (SRNE), Myovant Sciences (MYOV), CEL-SCI (CVM), Agile Therapeutics (AGRX), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Energy Transfer LP Unit (ET), Gilead Sciences (GILD) and Novavax (NVAX). Who are Savara's key executives? Savara's management team includes the following people: Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)Taneli Jouhikainen, President, Chief Operating Officer (Age 51)David L. Lowrance, Chief Financial Officer (Age 50)Nevan C. Elam, Independent Director (Age 49)Richard J. Hawkins, Independent Director (Age 68)Joseph S. McCracken Ph.D., Independent Director (Age 64)Matthew Pauls J.D., Independent Director (Age 46)Yuri Pikover, Independent Director (Age 56) What is Savara's stock symbol? Savara trades on the NASDAQ under the ticker symbol "SVRA." How do I buy shares of Savara? Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Savara's stock price today? One share of SVRA stock can currently be purchased for approximately $2.04. How big of a company is Savara? Savara has a market capitalization of $103.71 million. The company earns $-78,170,000.00 in net income (profit) each year or $4.57 on an earnings per share basis. View additional information about Savara. What is Savara's official website? The official website for Savara is http://www.savarapharma.com/. How can I contact Savara? Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-614-1848 or via email at [email protected] This page was last updated on 4/8/2020 by MarketBeat.com StaffFeatured Article: Insider Trading
